title: Early identification of hERG liability in drug discovery programs by automated patch clamp.
abstract: Blockade of the cardiac ion channel coded by human ether-à-gogo-related gene (hERG) can lead to cardiac arrhythmia, which has become a major concern in drug discovery and development. Automated electrophysiological patch clamp allows assessment of hERG channel effects early in drug development to aid medicinal chemistry programs and has become routine in pharmaceutical companies. However, a number of potential sources of errors in setting up hERG channel assays by automated patch clamp can lead to misinterpretation of data or false effects being reported. This article describes protocols for automated electrophysiology screening of compound effects on the hERG channel current. Protocol details and the translation of criteria known from manual patch clamp experiments to automated patch clamp experiments to achieve good quality data are emphasized. Typical pitfalls and artifacts that may lead to misinterpretation of data are discussed. While this article focuses on hERG channel recordings using the QPatch (Sophion A/S, Copenhagen, Denmark) technology, many of the assay and protocol details given in this article can be transferred for setting up different ion channel assays by automated patch clamp and are similar on other planar patch clamp platforms.
authors.affiliation: NMI TT GmbH Reutlingen, Germany.
authors.forename: Timm
authors.initials: T
authors.lastname: Danker
authors.affiliation: Life Sciences Faculty, Albstadt-Sigmaringen University of Applied Sciences Sigmaringen, Germany.
authors.forename: Clemens
authors.initials: C
authors.lastname: Möller
keywords: ADMET; Torsades de Pointes; automated patch clamp; cardiac arrhythmia; electrophysiology; hERG; ion channel; safety pharmacology